RTS Life Science, a pharmaceutical automation specialist company, has appointed Gary Walsh as its new managing director
Phil Johnson, Walsh's predecessor, retired after 17 years with the RTS Group.
Gary has held the position of RTS Life Science's sales director for the last six years and has focussed on building collaborative partnerships with companies such as AstraZeneca, GSK and Novartis.
He commented: "Within the life science sector, RTS is regarded as a sizeable company with a large, highly skilled technical team that is able to take on big, often leading edge, projects.
"My immediate priority is to ensure we have the right structure for growth and to give much greater emphasis to our market offerings, especially our products.
"Years of project-based delivery have given us a great deal of valuable intellectual property and we have already begun exploiting this, specifically in the drug delivery automation and biobanking arenas.
"I expect to work with the management team to find more opportunities such as these so that we can increase our product range and therefore market reach".
